Takeda has secured its first approval outside Japan for a vaccine. Photograph: Laurie Dieffembacq / AFP via Getty ImagesTakeda has said approval of its dengue fever vaccine in Indonesia marks a big step towards the company’s goal of creating a global vaccine business that would compete with larger rivals such as GSK, Sanofi and Merck.
Anticipated approvals by regulators in Europe and elsewhere would make the vaccine a key weapon in the global battle against the mosquito-borne disease that infects up to 400 million people and kills about 20,000 a year, he said. Analysts say Takeda faces a challenge to deliver on its decade-old strategy to compete with more established international rivals in the global vaccine market.
“Takeda’s policy is very clear on vaccines. It’s a step-by-step approach so they won’t take big risks to invest aggressively in everything,” said Citigroup analyst Hidemaru Yamaguchi in Tokyo. As a result, its pipeline may be slim and its expansion slow as it aims to turn a promising vaccine into a global cash cow.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: IrishTimesBiz - 🏆 6. / 77 Read more »
Source: IrishTimesBiz - 🏆 6. / 77 Read more »